SCHOTT investiert in hochmoderne Spritzenproduktion
Donnerstag, 10. März 2022, LUKÁCSHÁZA, UNGARN/MAINZ, DEUTSCHLAND
- Die Investition in Höhe von 76 Millionen Euro in Ungarn soll weltweit steigende Nachfrage nach vorfüllbaren Glasspritzen decken
- Kapazitätserweiterung am bestehenden Standort von SCHOTT in Lukácsháza geplant
In light of the growing demand for drug delivery solutions, the international technology group SCHOTT is again investing in its pharma business: The company is planning to build an entirely new production for high-quality prefillable glass syringes (PFS) in Hungary. “The added capacity will greatly benefit the global market and strengthen supply security for major pharmaceutical companies and contract manufacturing organizations,” said Andreas Reisse, Executive Vice President of SCHOTT’s Pharma business unit. The double-digit million Euro amount is supported by the local government with about nine million Euros (3,321 billion HUF). The expansion is scheduled for completion in 2024 and is designed to create 120 new jobs.
Hochwertige Lösungen, mit denen sich Medikamente sicher aufbewahren und injizieren lassen, sind wesentlicher Bestandteil eines jeden Medikaments. Typically, a new drug enters the market in a vial and a single-use syringe is used to extract and administer it. In the mid-to-long term, these drugs may be stored in syringes that are prefilled with the medication. This simplifies the injection process for healthcare workers and increases dosing accuracy for the patient, as the syringe is already readily prepared. “High-quality prefillable syringes are designed to ease the administration process, ultimately enhancing patient safety,” explains Christian Helbig, Head of Glass Syringes at SCHOTT’s Pharma business unit. “Our borosilicate glass PFS are used to safely store a wide range of drugs, including vaccines and biologics.”
Already today, SCHOTT’s Hungarian site in Lukácsháza plays an important role in supplying the global industry with drug containment systems and provides enough space for further capacity expansions to follow.
Building on the strong existing foundation and skillset, the production will be equipped with state-of-the-art machinery. As part of SCHOTT’s global production network in 13 countries, the manufacturing will follow high-end processes and advanced quality assurance.
Links:
More information on syriQ® prefillable glass syringes
Trademarks:
syriQ® is a registered trademark of SCHOTT AG.
Already today, SCHOTT’s Hungarian site in Lukácsháza plays an important role in supplying the global industry with drug containment systems and provides enough space for further capacity expansions to follow.
Building on the strong existing foundation and skillset, the production will be equipped with state-of-the-art machinery. As part of SCHOTT’s global production network in 13 countries, the manufacturing will follow high-end processes and advanced quality assurance.
Links:
More information on syriQ® prefillable glass syringes
Trademarks:
syriQ® is a registered trademark of SCHOTT AG.
